Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Genitourinary 1

Conditions

Sexuality 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Prostatic Neoplasms 1Erectile Dysfunction 1

Interventions

Cyclophosphamide 2064Radiotherapy 1984Cisplatin 1851Carboplatin 1557Gemcitabine 1452Paclitaxel 1320Bevacizumab 1316pembrolizumab 1235Docetaxel 1225Oxaliplatin 1181Capecitabine 1173Fluorouracil 1081Dexamethasone 979Magnetic Resonance Spectroscopy 967Nivolumab 936Rituximab 928Drug Therapy 911Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 814Blood Specimen Collection 814Irinotecan 783Cytarabine 743fludarabine 723Leucovorin 682Surgical Procedures, Operative 638Lenalidomide 618Biopsy 592fludarabine phosphate 568

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × ArginMax × Clear all
NCT00459134 2021-09-28

L-Arginine Supplements in Treating Women Who Are Cancer Survivors

Wake Forest University Health Sciences

Phase NA Completed
186 enrolled 11 charts
Other

Sexual Dysfunction, Physiological, Sexuality

NCT01105130 2021-09-28

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Wake Forest University Health Sciences

Phase 2 Completed
140 enrolled 13 charts
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡